Melo-Filho NM, Belmiro CL, Gonçalves RG, Takiya CM, Leite M Jr, Pavão MS, Mourão PA. Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event? Am J Physiol Renal Physiol 299: F1299 -F1307, 2010. First published September 22, 2010 doi:10.1152/ajprenal.00217.2010.-Fibrosis is the end point of most renal diseases, and several glycosaminoglycans have been shown to attenuate this process. Marine invertebrate glycosaminoglycans with unique structures have opened the possibility to test these new compounds on renal fibrosis. The effect of a fucosylated chondroitin sulfate from an echinoderm marine species is reported with the use of a model of renal fibrosis in rats, termed unilateral ureteral obstruction. Animals were given 4 mg/kg body wt of fucosylated chondroitin sulfate intraperitoneally, once a day. After 14 days, their kidneys were examined by histological, immunohistochemical, and biochemical methods. Compared with control mice, collagen deposition decreased in the course of renal fibrosis in the animals receiving fucosylated chondroitin sulfate, as revealed by Sirius red staining and hydroxyproline content. The cellularity related to myofibroblasts and macrophages was also reduced, as was the production of transforming growth factor (TGF)-␤. The glycosaminoglycan content increased in the renal interstitium of animals submitted to unilateral ureteral obstruction compared with the control contralateral kidney, mostly due to an increase of chondroitin sulfate content. Interestingly, no change in the pattern of glycosaminoglycan deposition was observed after administration of fucosylated chondroitin sulfate. Fibrosis induced by unilateral ureteral obstruction is attenuated in P-selectin-deficient mice, which also do not respond to the invertebrate glycosaminoglycan. In conclusion, fucosylated chondroitin sulfate attenuates renal fibrosis on a ureteral obstruction model in mice preponderantly through a P-selectinmediated mechanism.
The use of glycosaminoglycans as anti-inflammatory agents has been tested in different models of renal disease. In subtotal nephrectomized rats, heparin ameliorates glomerular sclerosis and interstitial fibrosis (1) . Low-molecular-weight heparin decreases proteinuria in adriamycin-induced renal disease (3) and attenuates fibrosis in the unilateral ureteral obstruction model in rats (21) .
Sulfated polysaccharides with unique structures have been isolated from marine invertebrates in our laboratory (17, 22) . The availability of these compounds prompted us to investigate their therapeutic effect in diverse pathological contexts. The results of these works revealed glycans with different therapeutic potentials. For example, a fucosylated chondroitin sulfate isolated from sea cucumbers (25, 26) attenuates thrombosis, by inhibiting thrombin in a serpin-mediated mechanism (18, 19) , and tumor metastasis, possibly by a P-and/or Lselectin-dependent mechanism (5), respectively. In addition, we have recently shown that an oversulfated dermatan sulfate from tunicate attenuates colitis in rats by reducing macrophage and lymphocyte recruitment, tumor necrosis factor (TNF) and transforming growth factor (TGF)-␤ production, and collagen deposition in inflamed colon (2) . We speculated that the anti-selectin activity is a prevalent factor, which accounts for the anti-inflammatory effect of the invertebrate glycans, reducing the recruitment of inflammatory cells to the site of inflammation.
To obtain additional evidence to support this hypothesis, in the present study we evaluated the progression of kidney inflammation in wild-type or P-selectin-deficient mice 14 days after unilateral ureteral obstruction, before or after treatment with fucosylated chondroitin sulfate from sea cucumber, which has a potent anti-selectin activity (5) . Our results indicate that the invertebrate glycosaminoglycan reduces the recruitment of inflammatory cells and attenuates interstitial fibrosis in wildtype animals. In contrast, in P-selectin-deficient animals, inflammation is drastically reduced and the protective effect of the echinoderm chondroitin sulfate is not observed. We propose that fucosylated chondroitin sulfate acts at an initial inflammatory stage, possibly by reducing the selectin-mediated leukocyte interaction with the renal endothelium.
MATERIALS AND METHODS

Animals and experimental protocols.
A total of 190 healthy male adult Swiss mice around 12 wk old and weighing ϳ20 g underwent left ureteral obstruction or served as sham-operated and control saline-treated animal groups. Briefly, mice were anesthetized by intramuscular injection of ketamine (35 mg/kg body wt) and xylazine (9 mg/kg body wt). Under sterile conditions, an abdominal midline incision was made. The left ureter was exposed and ligated using 4-0 silk at two points; the ureter was sectioned between the ligatures. The skin was sutured for approximation, and the mice were kept in regular cages. The mice were divided into five groups, as follows: 1) control: nonunilateral ureteral obstruction, nontreated mice (n ϭ 5); 2) sham operated (n ϭ 5); 3) group submitted to unilateral ureteral obstruction but with no treatment (n ϭ 5); 4) group with unilateral ureteral obstruction and receiving 100 l of sterile saline given intraperitoneally once a day (n ϭ 5); and 5) group submitted to unilateral ureteral obstruction and receiving 4 mg/kg body wt of fucosylated chondroitin sulfate, dissolved in 100 l of sterile saline, given intraperitoneally once a day. Sham-operated animals underwent identical surgical procedures, except that the left ureter was manipulated without ligation and sectioning. Control mice underwent no surgical manipulation. Mice were kept in a 12:12-h light-dark cycle at 25°C and fed a standard mouse chow and water ad libitum. The animals were euthanized with ketamine (35 mg/kg body wt) and xylazine (9 mg/kg body wt) given by intramuscular injection, and the kidneys were removed 14 days after unilateral ureteral obstruction or sham operation. All experimental procedures were approved by the independent review committee and conducted in accordance with the institutional guidelines of Universidade Federal do Rio de Janeiro, Centro de Ciências da Saúde.
In another set of experiments, P-selectin-deficient mice (B6.12B6.129S7-SelpϽtm1BayϾ/J9S7-SelpϽtm1BayϾ/J) obtained from the Jackson Laboratory (Bar Harbor, ME) were used. The animals were divided into six groups (n ϭ 4 each): 1) P-selectin ϩ/ϩ mice with nonunilateral ureteral obstruction, 2) P-selectin ϩ/ϩ mice subjected to ureteral obstruction and receiving 100 l of sterile saline given intraperitoneally once a day, 3) P-selectin ϩ/ϩ mice subjected to ureteral obstruction and receiving 4 mg/kg body wt of fucosylated chondroitin sulfate once a day, 4) P-selectin Ϫ/Ϫ mice with nonureteral obstruction, 5) P-selectin Ϫ/Ϫ mice subjected to ureteral obstruction and receiving saline, and 6) P-selectin Ϫ/Ϫ mice subjected to ureteral obstruction and receiving 4 mg/kg body wt of fucosylated chondroitin sulfate once a day. The animals were euthanized after 14 days of unilateral ureteral obstruction and the kidneys removed, as described above. Fucosylated chondroitin sulfate was tested for side effects in mice. No visible abnormalities were observed during intraperitoneal administration of the echinoderm compound at a dose 10-fold higher than that used in the protocol to prevent renal fibrosis, even after a period of 30 days. In addition, no immune response to the invertebrate glycosaminoglycan was observed. Fucosylated chondroitin sulfate was also tested for effects on the cardiovascular system. Animals receiving a single dose of fucosylated chondroitin sulfate (3.5 mg/kg body wt) showed an ϳ40% drop in arterial pressure immediately after intravenous injection of the polysaccharide. A decrease in heart rate was also noted (14) . However, when fucosylated chondroitin sulfate was given intraperitoneally, no change of blood pressure or heart rate was detected over a period of 4 h.
Tissue preparation. After 14 days of unilateral ureteral obstruction, arterial blood (450 l) was collected from the left cardiac ventricle for anticoagulation analysis and immediately inserted in tubes with 50 l of 3.8% sodium citrate. Animals were perfused with sterile saline via the left cardiac ventricle, followed by infusion of a 4% buffered paraformaldehyde solution for 20 min. Kidneys were removed and sectioned midfrontally into two pieces. One fragment was immediately fixed overnight in 10% buffered formaldehyde, and the other was conserved in acetone. Samples were dehydrated with ethanol, treated with xylene, and embedded in paraffin at 56°C. Three-micrometer-thick sections were processed for either routine staining or immunostaining. Kidney tissue specimens were prepared for light microscopy evaluation using hematoxylin-eosin and Sirius red staining for collagen detection.
Histomorphometry and collagen network. Histomorphometry was performed using an imaging analysis system composed of a digital camera (Coolpix 990; Nikon, Tokyo, Japan) coupled to a light microscope (Eclipse 400; Nikon). A total of 20 fields from each animal, 10 of renal cortex and 10 of medulla, were used for immunohistochemistry and Sirius red-stained sections. The sections were captured using a magnification ϫ40 objective lens. The interstitial area of renal cortex and medulla occupied by collagen was quantified in Sirius red-stained sections by using a point-counting technique described previously (10, 11) . All the quantifications were done using captured high-quality images (2,048 ϫ 1,536-pixel buffer) with Image-Pro Plus 4.5.1 (Media Cybernetics, Silver Spring, MD). Morphological measurement was performed blindly by a single observer. Differences in the background do not affect the accuracy of the histomorphometry. The changes reported affect renal cortex and medulla of the kidney at similar intensities.
Determination of hydroxyproline. The content of hydroxyproline was estimated using a modified method described by Stegemann and Stalder (24) . Briefly, the samples were immersed in acetone for 24 h at 4°C and dried in an oven at 60°C. About 15 mg of individual samples were subjected to acid hydrolysis with 1 ml of 6 N HCl at 107°C for 18 h. The HCl was removed by evaporation, and the hydrolyzed material was mixed with 400 l of the following solution: 5% citric acid·1H 2O, 1.2% acetic acid, 12% sodium acetate·3H2O, and 3.4% sodium hydroxide, pH 6.0, 1:10 diluted. The mixture was divided into two aliquots of 200 l and incubated with 1 ml of chloramine-T solution for 20 min at room temperature. Thereafter, 1 ml of aldehyde/perchloric acid solution was added and incubated for another 15 min at 60°C. The absorbance at 570 nm was then read after 20 min. The concentration was estimated by a standard curve using a pure solution of hydroxyproline, and the results are expressed in micrograms per milligram of dry weight.
Immunohistochemistry. Interstitial cellularity was characterized and quantified for macrophages in the cortex and medulla of renal tissue with F4/80 rat anti-mouse macrophage monoclonal antibody (Serotec, Oxford, UK). Interstitial myofibroblasts were measured with ␣-smooth muscle actin monoclonal antibody (Dako, Carpinteria, CA). TGF-␤1 was assessed using pan-specific antibody against TGF-␤ (R&D Systems). Paraffin-embedded sections (3 m) were cut onto glass slides. The sections were dewaxed in xylene three times for 15 min each, rehydrated in decreasing concentrations of ethanol for 5 min, and washed 3 times in phosphate-buffered saline (PBS) for 10 min. Endogenous peroxidase was quenched for 30 min with 0.3% methanol. After sections were washed in filtered water and PBS, a blocking step was included using 5% bovine serum albumin (BSA) in PBS for a total of 30 min. Primary antibody against specific antigens described above was then incubated overnight at 4°C in a humidified chamber. Negative controls were carried out with BSA instead of primary antibody. After room temperature was achieved, sections were washed in 0.25% PBSTween solution for 5 min. For F4/80 antibody, biotinylated rabbit anti-mouse secondary antibody (Vector) was incubated for 45 min, followed by incubation with avidin-biotin peroxidase complex (Vector Laboratories). For ␣-smooth muscle actin and TGF-␤, the LSAB 2 System-HRP kit (catalog no. KO609; Dako) was used. Reactions were revealed using diaminobenzidine chromogen substrate (Sigma Fast DAB; Sigma, St. Louis, MO). After the slides were washed, counterstaining was done with 10% hematoxylin for 1-2 min. The quantification of F4/80-positive cells was carried out in a blinded fashion under ϫ400 magnifications and expressed as the number of cells per field. Myofibroblast and TGF-␤ surface density was obtained by considering the percentage of stained areas in the total of histological fields. Cell leakage refers to the number of total cells per square millimeter based on the nucleus staining using hematoxylin-eosin.
Western blot analysis. Kidney tissues were homogenized in the extraction buffer (20 mM Tris·HCl, 10% SDS, 0.1% Triton X-100, and protease inhibitor cocktail; Sigma) on ice. The proteins were then precipitated with 10% TCA for 20 min at 4°C, and the supernatant was discarded. The pellet was resuspended in 5 M urea-HCl, pH 6.0, containing 0.1% SDS. Protein concentration was estimated using the Bradford protein assay kit (Bio Agency). Protein samples (100 g protein/lane) were electrophoresed through a 7.5% polyacrylamide gel and then transferred to a nitrocellulose membrane (Amersham France, Les Ulis, France). The membrane was blocked with 5% skim milk powder for 1 h and then incubated overnight at 4°C with primary polyclonal rabbit anti-TGF-␤ antibody (1.5 g/ml; R&D Systems) and mouse monoclonal anti-␤-actin antibody (1:1,000; Santa Cruz Biotechnology). The immune complexes were detected using a peroxidase-conjugated secondary antibody (GE Healthcare, Little Chalfont UK). Positive immunoreactive bands were quantified densitometrically and normalized by ␤-actin.
Isolation and quantification of glycosaminoglycans. Pooled dried renal samples from five animals of each group (ϳ1 g) were suspended in 20 ml of 0.1 M sodium acetate buffer (pH 5.5) containing 100 mg of papain, 5 mM EDTA, and 5 mM cysteine and then incubated at 60°C for 24 h. The mixtures were centrifuged (2,000 g for 20 min at room temperature). Another 100 mg of papain in 20 ml of the same buffer, containing 5 mM EDTA and 5 mM cysteine, was added to the precipitate. The mixture was then incubated for another 24 h. The clear supernatants from the two extractions were combined, and the glycosaminoglycans were precipitated with a solution of 0.5% cetylpyridinum chloride in water, followed by 2 vols of 95% ethanol, and maintained at 4°C for 24 h. The precipitate formed was collected by centrifugation (2,000 g for 10 min at room temperature), freeze-dried, and dissolved in 2 ml of distilled water. The amount of glycosaminoglycans in the renal samples was estimated by the content of hexuronic acid (g/mg dry weight) using the carbazole reaction (4) .
Analysis of the glycosaminoglycans by agarose gel electrophoresis. The glycosaminoglycans extracted from the different renal samples were analyzed by agarose gel electrophoresis, as described previously (9) . Briefly, about 1.5 g (as uronic acid) of the glycans and a mixture of standard glycosaminoglycans containing chondroitin 4-sulfate, dermatan sulfate, and heparan sulfate (1.5 g as uronic acid of each) were applied to a 0.5% agarose gel in 0.05 M 1,3-diaminopropane/acetate (pH 9.0) and run for 1 h at 100 V. After electrophoresis, the glycosaminoglycans were fixed with aqueous 0.1% cetyltrimethylammonium bromide solution and stained with 0.1% toluidine blue in acetic acid-ethanol-water (0.1:5:5, vol/vol/vol). To identify the glycosaminoglycans that formed the observed bands, an enzymatic treatment was applied using chondroitin AC and ABC lyases, which cleave specifically chondroitin 4/6-sulfate and chondroitin 4/6-sulfate ϩ dermatan sulfate, respectively, and nitrous acid, which cleaves heparan sulfate.
Ex vivo anticoagulating activity. Three different doses of fucosylated chondroitin sulfate (4, 8, and 24 mg/kg body wt, which are similar or 2-and 6-fold the doses used to prevent renal fibrosis in this study, respectively) were administered intraperitoneally to mice. Blood samples were collected before the infusion of fucosylated chondroitin sulfate and at intervals of 30 min up to 240 min. The anticoagulant activity of the plasma was determined by the activated partial thromboplastin time (aPTT) assay. Briefly, 100 l of plasma were incubated with 100 l of activated cephalin (Reagent Celite; Biolab, Mérieux, France) for 2 min. Thereafter, 100 l of 0.25 M CaCl 2 were added to the mixture, and the clotting time was evaluated on a microcoagulometer (model KC4A; Amelung, Lemgo, Germany). In another set of experiments, plasma samples were drawn before and 14 days after unilateral ureteral obstruction. The clotting time was registered as described previously, and the results are expressed as T 1/T0 where T1 and T0 are the clotting times after and before fucosylated chondroitin sulfate infusion, respectively.
Statistics. All the data are given as median (maximum and minimum) values. Comparisons between two groups were done using the Mann-Whitney test, and those among groups were done using ANOVA or the Kruskal-Wallis test for parametric and nonparametric data, respectively. Posttests were done using Tukey's test. Bar graphs represent parametric data, and box plots represent nonparametric data. Results were considered significant when P Ͻ 0.05.
RESULTS
Collagen deposition. Sirius red staining showed higher density in renal interstitium of mice submitted to unilateral ureteral obstruction for 14 days compared with renal interstitium of nonobstructed animals (Fig. 1, A and B) . Kidneys from mice receiving fucosylated chondroitin sulfate at a dose of 4 mg/Kg body wt, given intraperitoneally once a day, showed a marked decrease of Sirius red staining compared with those of salinetreated animals (Fig. 1, B and C) . The histopathological aspects of renal tissues and the histomorphometries are shown in Fig.  1, A-C and D, respectively. Collagen content was also estimated by hydroxyproline ( Fig. 2A) . Again, the results indicated that the amount of collagen increased significantly in renal tissues after 14 days of unilateral ureteral obstruction compared with that in control, nonobstructed animals. Mice treated with fucosylated chondroitin sulfate showed a marked decrease in collagen accumulation. Figure 2B shows the time course increase of hydroxyproline content in renal tissue of animals submitted to unilateral ureteral obstruction. The collagen content increased gradually, reaching levels higher than those observed in kidneys from nonobstructed and sham-operated animals after 14 days of obstruction. Treatment of the animals with fucosylated chondroitin sulfate reduced renal collagen accumulation compared with that in saline-treated animals.
Abundance of macrophages, myofibroblasts, and TGF-␤. We evaluated the content of macrophages and myofibroblasts in the kidney using specific antibodies. Immunohistochemical staining with F4/F80 antibody was employed to evaluate the abundance of macrophages. After 14 days, the number of macrophages clearly increased in the kidney of mice submitted to unilateral ureteral obstruction compared with that in kidney from nonobstructed animals, as indicated by the high amounts of F4/80-positive cells (Fig. 3, A and B) . Quantification of the stained area allowed us to obtain numerical values (Fig. 3D) . The number of macrophages in the renal interstitium decreased significantly in the kidney of mice treated with fucosylated chondroitin sulfate for 14 days compared with that from saline-treated animals (Fig. 3, B and C) . The numeric values are shown in Fig. 3D . The abundance of myofibroblasts was evaluated using anti-␣-smooth muscle actin antibody. Figure 4 , A and B, shows the histopathological images of kidney from control, nonobstructed mice and from animals submitted to unilateral ureteral obstruction for 14 days, respectively. Clearly, the amounts of ␣-smooth muscle actin-positive cells increased in the kidney from obstructed animals. Again, treatment with fucosylated chondroitin sulfate reduced the number of myofibroblasts in the renal interstitium (Fig. 4C) . The numerical values are shown in Fig. 4D .
Finally, we also evaluated the abundance of TGF-␤1 in the renal tissue (Fig. 5) . The amount of TGF-␤1 increased after 14 days of unilateral ureteral obstruction (Fig. 5, A and B) , and this effect was partially attenuated by treatment with fucosylated chondroitin sulfate (Fig. 5, B and C) . The numerical values are shown in Fig. 5D . TGF-␤1 production was also evaluated using Western blot analysis (Fig. 5, E and F) , which indicated that fucosylated chondroitin sulfate slightly decreased TGF-␤1 levels compared with saline control, but not to the level seen in the nonobstructed animals.
Renal glycosaminoglycans. The total amount of glycosaminoglycans in renal tissue, indicated by hexuronic acid content, increased ϳ2-fold after 14 days of unilateral ureteral obstruction compared with nonobstructed and sham-operated animals (Fig. 6) . Treatment of mice with fucosylated chondroitin sulfate did not promote any significant modification in the content of total renal glycosaminoglycan compared with that in obstructed kidneys of saline-treated animals. The identity of the glycosaminoglycan population found in the kidney tissue was analyzed by agarose gel electrophoresis. Kidneys from untreated animals contain exclusively heparan sulfate, as indicated by a single metachromatic band that comigrates with that of heparan sulfate standard (Fig. 7A) . The identity of this glycosaminoglycan was confirmed by enzymatic deamination treatment, showing that it resists chondroitin AC and ABC lyases but is cleaved by deamination with nitrous acid (Fig.  7C) . Obstructed kidneys show the presence of an additional metachromatic band that comigrates with that of standard dermatan sulfate (Fig. 7B) . Cleavage with chondroitin AC and ABC lyases confirmed the identity of this glycosaminoglycan in the obstructed kidney (Fig. 7D) . Contralateral, nonobstructed kidneys contain exclusively heparan sulfate (Fig. 7B) . Administration of fucosylated chondroitin sulfate did not modify the total amounts or the type of glycosaminoglycans of the kidney (Figs. 6 and 7B) .
Anticoagulant effect of fucosylated chondroitin sulfate. The anticoagulant effect of fucosylated chondroitin sulfate was determined by the aPTT assay in mouse plasma, at intervals of 30 min, after intraperitoneal administration of 4, 8, and 24 mg/kg body wt of the invertebrate glycosaminoglycan. Clearly, the anticoagulant effect of fucosylated chondroitin sulfate was observed only in a dose far higher than that used to prevent kidney fibrosis. The doses of 4 and 8 mg/kg body wt did not modify the aPTT time. Administration of fucosylated chondroitin at the dose of 24 mg/kg body wt, which is 6-fold higher than that required to prevent renal fibrosis, changes aPTT time (closed circles in Fig. 8 ). Unfractionated heparin administered by intravascular route at a dose of 0.5 mg/kg body wt significantly changed the aPTT (Fig. 8 , open squares) in ex vivo experiments. To evaluate a possible accumulative effect of fucosylated chondroitin sulfate on aPTT, we collected blood samples 14 days after administration of the glycosaminoglycan. The ex vivo anticoagulant activity clearly showed that there was no significant change in aPTT after 14 days of daily intraperitoneal administration of 4 mg/kg body wt (not shown).
P-selectin-deficient mice show an attenuated renal fibrosis response. To evaluate the contribution of P-selectin to renal response to unilateral ureteral obstruction, we used P-selectindeficient mice. Obstructed kidneys of these animals showed a significantly lower collagen deposition and reduced inflammatory cellularity in the renal interstitium compared with the contralateral, nonobstructed kidneys (Fig. 9 ). Contrary to P-selectin ϩ/ϩ mice, P-selectin-deficient animals do not respond to treatment with fucosylated chondroitin sulfate.
Overall, the results of the present work clearly indicate that P-selectin plays an important role in the renal inflammatory and fibrotic responses in the course of unilateral ureteral obstruction and that treatment with fucosylated chondroitin sulfate significantly attenuates the progression of kidney fibrosis.
DISCUSSION
The beneficial effects of glycosaminoglycans have been well documented in several experimental models of pathological processes. In particular, heparin has anti-inflammatory and antiproliferative effects, as well as a renal protective action, in models of glomerular disease (7, 20) . Low-molecular-weight heparin attenuated the development of interstitial fibrosis in animals submitted to unilateral ureteral obstruction. However, the mechanism of this protective effect was not investigated in detail. Each type of glycosaminoglycan may have a particular effect on renal fibrosis, perhaps due to distinct mechanisms of action. For example, unfractionated heparin, but not lowmolecular-weight heparin, reduces the increased glycosaminoglycan deposition in obstructed kidneys, whereas both glycosaminoglycans prevent collagen synthesis (21). We have now tested a distinct glycosaminoglycan, obtained from an echinoderm, on mice submitted to unilateral ureteral obstruction. This glycosaminoglycan is composed of a central carbohydrate core similar to mammalian chondroitin sulfate, which contains unique sulfated fucose branches that provide distinct biological properties to this compound (19, 26) .
Fucosylated chondroitin sulfate has several advantages over heparin as a therapeutic agent against kidney fibrosis. It has a reduced anticoagulant activity (19) and a stronger inhibitory 7 . Characterization of the renal glycosaminoglycans by agarose gel electrophoresis, digestion with chondroitin AC and ABC lyases (Chase AC and Chase ABC, respectively) and deamination with nitrous acid. A: glycosaminoglycans extracted from control, nonobstructed kidney and a mixture of standard glycosaminoglycans, containing chondroitin 4-sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS), 1.5 g, as uronic acid of each, were applied to a 0.5% agarose gel in 0.05 M 1,3-diaminopropane/acetate (pH 9.0) and run for 1 h at 100 V. After electrophoresis, the glycosaminoglycans were fixed with aqueous 0.1% cetyltrimethylammonium bromide solution and stained with 0.1% toluidine blue. B: glycosaminoglycans extracted from the kidneys of animals submitted to unilateral ureteral obstruction (ϩ) or from the nonobstructed, contralateral kidneys (Ϫ) were analyzed by agarose gel electrophoresis, as described above. C and D: renal glycosaminoglycans extracted from nonobstructed kidneys of control animals (C) or from obstructed kidneys (D) were incubated with (ϩ) or without (Ϫ) Chase AC, Chase ABC, or deamination with nitrous acid and then submitted to agarose gel electrophoresis. effect on P-or L-selectin function (5, 6) compared with heparin. Fucosylated chondroitin sulfate is four to eight times more potent than heparin as an inhibitor of the interaction between P-and L-selectin with sialyl Lewis X ligands (6) . From a practical point of view, the advantages of this compound over heparin are its absorption by oral route (13) and the fact that it is not obtained from mammals, which reduces the risk of contamination with prions and viral particles. The effect of the echinoderm glycosaminoglycan on mice submitted to unilateral ureteral obstruction was followed using specific assays based on determination of collagen and glycosaminoglycan deposition on the extracellular matrix and on evaluation of inflammatory cells recruitment and TGF-␤ production in the renal interstitium. Furthermore, we employed P-selectin-deficient mice to investigate the mechanism of action of fucosylated chondroitin sulfate on the renal fibrosis. Clearly, the effect of fucosylated chondroitin sulfate on renal fibrosis is not related to its anticoagulant effect but possibly depends on its interaction with selectin. A more direct evidence for the relationship between P-selectin and the effect of fucosylated chondroitin sulfate is required. In further support of our proposition is the observation that vertebrate chondroitin sulfate, devoid of the sulfated fucose branches, does not bind selectin (6) and is also devoid of the protective effect on renal fibrosis (data not shown). The effect of other sulfated polysaccharides on inflammation has been attributed to their inhibitory action on P-and L-selectins (27) . Sulfated hyaluronic acid inhibits selectin-sulfatide binding and attenuates the infiltration of lymphocytes and macrophages in a model of mesangial proliferative glomerulonephritis (16) . Furthermore, the integrity of endothelial heparan sulfate domains is crucial for leukocytes infiltration (28) . A recent study by Rops et al. (23) , using a murine model of nephritis, has addressed this issue. The presence of N-and 6-O-sulfated domains of endothelial heparan sulfate is required for the rolling and infiltration of leucocytes into the site of injury.
Our proposition is that fucosylated chondroitin sulfate inhibits the selectin-mediated initial binding event that directs the movement of leukocytes across the endothelium in the injured renal tissue. The glycosaminoglycan decreases macrophage infiltration in the renal interstitium of obstructed kidney and therefore reduces the production of TGF-␤1. Interstitial myofibroblasts can derive from either systemic or resident fibroblasts or transdifferentiated epithelial cells by epithelial-tomesenchymal transition. This last effect has been documented as being related to the release of TGF-␤ (12). We believe that production of TGF-␤ by resident kidney cells is not preponderantly affected by treatment with fucosylated chondroitin sulfate. In this case, the P-selectin-deficient mice would respond to the treatment with fucosylated chondroitin sulfate, which was not observed (Fig. 9) . P-selectin-deficient mice still showed a residual renal collagen deposition and cellular response to that for the unilateral ureteral obstruction, which is not prevented by treatment with fucosylated chondroitin sulfate. Possibly, there is a distinct but less preponderant mechanism involved in the renal fibrosis that is P-selectin independent and not inhibited by fucosylated chondroitin sulfate.
Neither qualitative nor quantitative differences were observed between glycosaminoglycans isolated from obstructed kidney of saline-and fucosylated chondroitin sulfate-treated animals. In contrast, collagen content increased markedly during the evolution of the renal fibrosis. These observations indicate that different mechanisms control glycosaminoglycan and collagen synthesis and deposition in the course of the renal disease, as has already been reported for other pathological processes (8) .
In conclusion, fucosylated chondroitin sulfate attenuates renal fibrosis on a unilateral ureteral obstruction model in mice through a preponderant selectin-mediated mechanism. This glycosaminoglycan may have a future application on prevention of renal fibrosis, especially in view of its decreased anticoagulant effect and its oral absorption.
